Publications
2024年度
論文・総説
・Uekusa S, Nakashin M, Hanai Y, Nemoto M, Yanagino S, Arita Y, Matsumoto T, Wakui N, Nagai H, Higai K, Matsuo K.Risk factors for lenvatinib-induced hypertension in patients with hepatocellular carcinoma: A retrospective study. Br J Clin Pharmacol. 2024 Nov 20. doi: 10.1111/bcp.16337.
・Nagumo H, Nagai H, Higai K, Matsuda T, Igarashi Y. Effects of Atezolizumab plus Bevacizumab on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma.Oncology. 2024 Oct 23:1-11. doi: 10.1159/000541674.
・Mukozu T, Nagai H, Nagumo H, Mohri K, Yoshimine N, Kobayashi K, Ogino Y, Matsui T, Daido Y, Wakui N, Momiyama K, Higai K, Matsuda T, Igarashi Y. The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma.Oncology. 2024 Sep 12:1-13. doi: 10.1159/000541372.
・Mohri K, Nagai H, Matsuda T, Igarashi Y, Higai K. Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab.Anticancer Res. 2024 Sep;44(9):3919-3929. doi: 10.21873/anticanres.17220.
・Uekusa S, Nemoto M, Hanai Y, Nakashin M, Yanagino S, Arita Y, Matsumoto T, Wakui N, Nagai H, Higai K, Matsuo K..Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study. Cancer Med. 2024 Aug;13(16):e70065. doi: 10.1002/cam4.70065.
・Nagai H, Mukozu T, Matsui T, Mohri K, Nagumo H, Yoshimine N, Kobayashi K, Ogino Y, Daido Y, Wakui N, Momiyama K, Matsuda T, Igarashi Y, Higai K. Remaining Issues Related to Serum Cytokines in Patients with Unresectable Hepatocellular Carcinoma Treated by Atezolizumab plus Bevacizumab Combination Treatment. Oncology. 2024 doi: 10.1159/000537965.